论文部分内容阅读
据《自然》周刊报道,随着泛欧高增长公司股票市场的开放,欧洲百万富翁科学家也将成为寻常。 类似于美国的NASDAQ(全国证券商协会自动化行情行情系统),欧洲也希望复制美国的成功。NASDAQ曾促进了美国的三大高技术公司微软、英特尔和生物医药公司Amgen的发展。 主要面向高技术产业的法欧股票交易所现已被改名为EASDAQ(欧洲证券商协会自动化行情系统),预料它的开业将对欧洲的技术基础产生三方面的重大影响: 第一,将缓和欧洲高技术公司投奔美国。第二,使科学家能更容易地获得为新公司提供新创想的种子资金,第三,如果科学家所提出的新创想受到投资界的青睐的话,那么他们就可能一下子成为百万富翁。 新的交易是期望吸引诸如先进材料、生物技术、环保技术、网络服务以及医学技术和软件等领域的快速增长新公司。现已有大批公司在急切等待新的交易开市。其中包括比利时的生物技术诊疗公司“遗传革新公司”(Innogenetcs)。
According to “Nature” magazine reported that with the pan-European high-growth stock market opened up, European millionaire scientists will become commonplace. Similar to the U.S. NASDAQ (National Association of Securities Dealers Automated Quotes System), Europe also hopes to replicate the success of the United States. NASDAQ has contributed to the development of Amgen, the three major U.S. high-tech companies, Microsoft, Intel and biomedical companies. The French-European stock exchange, mainly for high-tech industries, has now been renamed EASDAQ (European Securities Dealers Association Automated Quotes System) and is expected to have three major implications for Europe’s technological base: First, easing Europe High-tech companies defected to the United States. Second, making it easier for scientists to get seed money for new ideas for new companies. And third, if scientists’ new ideas are favored by the investing community, they may suddenly become millionaires. The new deal is looking to attract new and rapidly growing companies in areas such as advanced materials, biotechnology, environmental technologies, web services and medical technology and software. Now a large number of companies are eagerly awaiting the opening of new trading. Among them are Innogenetcs, a biotech clinic in Belgium.